TOLREMO therapeutics AG (“TOLREMO”) is a Swiss biotechnology company that was spun out of ETH Zurich in 2017. Based on cutting-edge science and guided by pioneering real-world medicine, TOLREMO created a broad cancer drug resistance platform that provides a unique entry point into a major clinical problem. The company develops resistance-breaking add-on therapies that extend the therapeutic benefit of oncogene-targeting cancer drugs by eliminating resistance-causing persister cells (Adaptive Drug Resistance). TOLREMO’s unique drug resistance platform has the potential to catalyze a new wave of potent resistance-breaking molecules that will meaningfully extend the lives of patients suffering from cancer. To learn more visit www.tolremo.com.